Quantiphi & DDReg Partner to Streamline Life Sciences Regulatory Processes with AI

The collaboration aims to address regulatory challenges faced by pharmaceutical companies, biotechnology firms, and manufacturers of medical devices and cosmetics.

Quantiphi, a global AI-driven digital engineering firm, has entered into a strategic partnership with DDReg, a leader in regulatory services, to expedite market innovations using AI.

The collaboration aims to address regulatory challenges faced by pharmaceutical companies, biotechnology firms, and manufacturers of medical devices and cosmetics.

Sharing thoughts, Neeti Pant, Managing Director of DDReg, said, “The collaboration harnesses our unparalleled regulatory knowledge and Quantiphi’s innovative technology, along with a deep understanding of artificial intelligence, to revolutionize regulatory processes. Together, we are transforming how the life sciences sector navigates some of its most pressing regulatory challenges, ensuring compliance, enhancing safety, and accelerating the time to market for new therapies.”

This collaboration, according to Pant, will not only address current regulatory demands but also anticipate future needs, providing a solid framework for sustainable growth and innovation.

“By combining our strengths, we are paving the way for a more streamlined, effective, proactive & cost-efficient approach to regulatory affairs in the life sciences industry,” he added.

Pant emphasized that the partnership is designed not only to meet current regulatory demands but to anticipate future needs, fostering sustainable growth and innovation in the industry.

Barinder Marhok, Global Head of Healthcare and Life Sciences at Quantiphi, said, "As the life sciences industry grapples with the ever-evolving regulation landscape, Quantiphi and DDReg have come together to help deliver cutting-edge solutions that streamline regulatory processes across both the drug development and commercialization lifecycle, ultimately helping improve more lives. Leveraging cloud, data and AI technologies, our joint efforts aim to accelerate approvals, enhance compliance and optimize life cycle management (LCM), ensuring a faster and more efficient path to market.’’

DDReg, a global leader in pharmaceutical regulatory services and pharmacovigilance, provides expertise across both developed and emerging markets, including the EU, USA, UK, Australia, Asia, Africa, and LATAM.

This collaboration is set to address critical regulatory challenges and improve efficiencies in the life sciences industry, ultimately helping bring innovative therapies to market faster and more safely.

Stay tuned for more such updates on Digital Health News.